Patent · US Active

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

US9090592B2 · kind B2 · utility

4Cited by

8References

29Claims

0Family size

Assignee

Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

Sean Colm Turner · Ludwigshafen, DE
Helmut Mack · Ludwigshafen, DE
Margaretha Henrica Maria Bakker · Ludwigshafen, DE
Marcel van Gaalen · Ludwigshafen, DE
Carolin Hoft · Ludwigshafen, DE
Wilfried Hornberger · Wiesbaden, DE

Key dates

Filing date	Dec 29, 2011
Grant date	Jul 28, 2015
Priority date	—
Expiry date	Dec 29, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D215/46
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to novel heterocyclic compounds of formula Iwherein the variables are as defined in the claims or the description,which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3β, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3β activity using the compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.